Biologic Product Exclusivity Decisions Will Involve Sponsor Dialogue, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While FDA has laid out the types of information it wants sponsors to provide, agency acknowledges it cannot easily write guidance stating the extent of structural changes to a molecule that would justify a new period of exclusivity.
You may also be interested in...
Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA
FDA’s embrace of biosimilars as part of the drug pricing response means a flurry of guidances coming soon. But don’t expect much clarity on key issues for innovators, like the boundaries of 12-year exclusivity and whether it will apply to NDA products that transition to BLAs, says a former CDER attorney.
Biologics Exclusivity: Key Questions Unlikely To Have Clear Answers From US FDA
FDA’s embrace of biosimilars as part of the drug pricing response means a flurry of guidances coming soon. But don’t expect much clarity on key issues for innovators, like the boundaries of 12-year exclusivity and whether it will apply to NDA products that transition to BLAs, says a former CDER attorney.
CDER Planning Guidances On Single-Trial Approvals, Real-World Evidence
US FDA drugs center’s ambitious guidance agenda lists 105 new or revised guidances, most of which carried over from the prior year; new to the list are three guidances each on real-world data and individualized antisense oligonucleotide drug products, and a document focused on demonstrating efficacy with a single adequate and well-controlled trial.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: